Mapping of brain tau deposition in tauopathy by PET with [11C]PBB3 - PBB3 3rd protocol

ational Institute of Radiological Sciences0 sites124 target enrollmentFebruary 14, 2013

ConditionsHealthy volunteers 20 years of age or older at the time of obtaining consent Patients with mild cognitive impairment (MCI) 20 years of age or older at the time of obtaining consent Patients with Alzheimer&#39 s disease (AD) 20 years of age or older at the time of obtaining consent Patients with corticobasal degeneration (CBD) 20 years of age or older at the time of obtaining consent Patients with progressive supranuclear palsy (PSP) 20 years of age or older at the time of obtaining consent Patients with frontotemporal dementia (FTD) 20 years of age or older at the time of obtaining consent Patients with familial Parkinson&#39 s disease with the LRRK2 genetic mutation (PARK8)

Overview

Phase: 未知
Intervention: Not specified
Conditions: Healthy volunteers 20 years of age or older at the time of obtaining consent Patients with mild cognitive impairment (MCI) 20 years of age or older at the time of obtaining consent Patients with Alzheimer&#39
Sponsor: ational Institute of Radiological Sciences
Enrollment: 124
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The distribution of tau PET ([11C]PBB3-PET) were consistent with pathological findings. The increased accumulation was associated with the severity of dementia and brain atrophy.

Registry

who.int

Start Date

February 14, 2013

End Date

March 31, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

ational Institute of Radiological Sciences

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•healthy volunteer 1\. Subjects with organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2\. Patients with substance\-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3\. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study. 4\. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.). 5\. Subjects with tattoos. Subjects with claustrophobia. 6\. Pregnant, possibly pregnant or lactating women. 7\. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study. 8\. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study. Patients with MCI, AD, CBD, PSP, FTD and PARK8 1\. Patients with other organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2\. Patients with substance\-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3\. Patients with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by doctors with responsibilities in this study. 4\. Patients with claustrophobia. 5\. Pregnant, possibly pregnant or lactating women. 6\. Patients who are considered to be inappropriate for participation by doctors with responsibilities in this study.